- Home
- MG vs ALLO Comparison
MG vs ALLO Comparison
Compare MG & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MG | ALLO |
|---|---|---|
| Founded | 1978 | 2017 |
| Country | United States | United States |
| Employees | N/A | 152 |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 531.0M | 570.1M |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MG | ALLO |
|---|---|---|
| Price | $21.67 | $1.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $8.35 |
| AVG Volume (30 Days) | 423.8K | ★ 4.9M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $700,970,000.00 | N/A |
| Revenue This Year | $5.47 | N/A |
| Revenue Next Year | $3.59 | $142,416.42 |
| P/E Ratio | $71.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.37 | $1.04 |
| 52 Week High | $21.57 | $4.46 |
Technical Indicators
Market Signals| Indicator | MG | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 70.44 | 36.06 |
| Support Level | $13.75 | $1.59 |
| Resistance Level | N/A | $1.92 |
| Average True Range (ATR) | 0.57 | 0.08 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 92.31 | 19.13 |
Price Performance
Historical ComparisonAbout MG Mistras Group Inc
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International, and Products and Systems, of which key revenue is derived from the North America segment. The North America segment provides asset protection solutions, including NDT, inspection, and mechanical and engineering services, along with software, digital, and data services.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).